The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma

European Journal of Haematology

Volumn 75, Issue 3, 2005, Pages 206-211

  Afsharian, Parvaneh ^a   Möllgård, Lars ^b   Hassan, Zuzana ^b   Xie, Hanjing ^a   Kimby, Eva ^b   Hassan, Moustapha ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Cancer Center Karolinska   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ciprofloxacin; Cyclophosphamide; Cytochrome P450; Drug drug interactions; Pharmacokinetic

Indexed keywords

4 HYDROXY CYCLOPHOSPHAMIDE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE DERIVATIVE; DOXORUBICIN; DRUG METABOLITE; IFOSFAMIDE; MAFOSFAMIDE; PREDNISOLONE; PRODRUG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HALF LIFE TIME; HIGH RISK PATIENT; HUMAN; INFECTION; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RELAPSE;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED;

EID: 23844520960     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00492.x     Document Type: Article

References (33)

1. BINOTTO G, TRENTIN L, SEMENZATO G. Ifosfamide and cyclophosphamide: effects on immunosurveillance. Oncology 2003;65:17-20.
2. SLADEK NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988;37:301-355.
3. SHIMADA T, YAMAZAKI H, MIMURA M, INUI Y, GUENGERICH FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
4. YU LJ, DREWES P, GUSTAFSSON K, BRAIN EG, HECHT JE, WAXMAN DJ. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. J Pharmacol Exp Ther 1999;288:928-937.
5. REN S, YANG JS, KALHORN TF, SLATTERY JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997;57:4229-4235.
6. CHANG TK, WEBER GF, CRESPI CL, WAXMAN DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993;53:5629-5637.
7. HOOPER DC, WOLFSON JS. Mode of action of the new quinolones: new data. Eur J Clin Microbiol Infect Dis 1991;10:223-231.
8. NORDEN CWFJ, BRYANT RE. Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin. Rev Infect Dis 1983;5:495-501.
9. CRUMP BWR, DENT J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 1983;24:784-786.
10. DESPLACES NGL, CARLET J, GUIBERT J, ACAR JF. The new quinolones and their combinations with other agents for therapy of severe infections. J Antimicrob Chemother 1986;17:25-39.
11. RUBIN JSG, YU VL, MUDER RR, MATADOR A, KAMERER DB. Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant externalotitis. Arch Otolaryngol Head Neck Surg 1989;115:1063-1069.
12. MCLELLAN RA, DROBITCH RK, MCLELLAN H, ACOTT PD, CROCKER JF, RENTON KW. Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation. Clin Pharmacol Ther 1995;58:322-327.
13. WIJNANDS WJ, VREE TB. Interaction between the fluoroquinolones and the bronchodilator theophylline. J Antimicrob Chemother 1988;22(Suppl. C):109-114.
14. MULDER GJ, NAGELKERKE JF, TIJDENS RB, WIJNANDS WJ, VAN DER MARK EJ. Inhibition of the oxidative metabolism of theophylline in isolated rat hepatocytes by the quinolone antibiotic enoxacin and its metabolite oxoenoxacin, but not by ofloxacin. Biochem Pharmacol 1988;37:2565-2568.
15. HARDER S, FUHR U, STAIB AH, WOLFF T. Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am J Med 1989;87:89S-91S.
16. JOLSON HM, TANNER LA, GREEN L, GRASELA TH Jr. Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch Intern Med 1991;151:1003-1004.
17. MCLELLAN RA, DROBITCH RK, MONSHOUWER M, RENTON KW. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996;24:1134-1138.
18. CARLENS S, RINGDEN O, ASCHAN J, et al. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination. Clin Transplant 1998;12:84-92.
19. XIE HJ, BROBERG U, GRISKEVICIUS L, et al. Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome p450 genes by ciprofloxacin. Bone Marrow Transplant 2003;31:197-203.
20. EKINS S, WRIGHTON SA. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 1999;31:719-754.
21. FEDERICO M, ETTORE MS. Lymphomas: Hodgkin and non-Hodgkin lymphomas. Epidemiol Prev 2004;28:92-96.
22. NIITSU N, IIJIMA K. Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study. Ann Hematol 2001;80:602-606.
23. MEYER RM, GYGER M, LANGLEY R, LESPERANCE B, CAPLAN SN. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 1998;30:591-600.
24. JOHANSSON M, BIELENSTEIN M. Determination of 4-hydroxycyclophosphamide in plasma, as 2,4-dinitrophenylhydrazone derivative of aldophosphamide, by liquid chromatography. J Chromatogr B Biomed Appl 1994;660:111-120.
25. GRISKEVICIUS L, MEURLING L, HASSAN M. Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma. Ther Drug Monit 2002;24:405-409.
26. HUITEMA AD, KERBUSCH T, TIBBEN MM, RODENHUIS S, BEIJNEN JH. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother Pharmacol 2000;46:119-127.
27. RICHTER T, SCHWAB M, EICHELBAUM M, ZANGER UM. Inhibition of human CYP2B6 by N,N′,N″-triethylenethiophosphoramide is irreversible and mechanism-based. Biochem Pharmacol 2005;69:517-524.
28. DING Q, KESTELL P, BAGULEY BC, et al. Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Cancer Chemother Pharmacol 2002;50:186-192.
29. CHUNG F, WANG LC, KESTELL P, BAGULEY BC, CHING LM. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4- acetic acid (DMXAA) in mice: the role of tumour necrosis factor. Cancer Chemother Pharmacol 2004;53:377-383.
30. CHEN TL, KENNEDY MJ, ANDERSON LW, et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Metab Dispos 1997;25:544-551.
31. SLATTERY JT, KALHORN TF, MCDONALD GB, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996;14:1484-1494.
32. HASSAN M, NILSSON C, OLSSON H, LUNDIN J, OSTERBORG A. The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma. Eur J Haematol 1999;63:163-170.
33. AYASH LJ, WRIGHT JE, TRETYAKOV O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992;10:995-1000.